Literature DB >> 9245956

MnDPDP for MR imaging of the liver. Results from the European phase III studies.

C G Torres1, B Lundby, A T Sterud, S McGill, P B Gordon, H S Bjerknes.   

Abstract

PURPOSE: To evaluate the diagnostic efficacy and safety of MnDPDP (Teslascan) in enhanced MR imaging.
MATERIAL AND METHODS: In 2 multiple independent trials in Europe 624 patients were given MnDPDP intravenously at 5 mumol/kg b.w. Patients underwent an unenhanced MR examination comprising T1-weighted spin-echo and breath-hold gradient-echo sequences and a T2-weighted spin-echo sequence. The T1 sequences were repeated after the administration of MnDPDP. In a subgroup of 137 patients the results of the enhanced MR images were compared with the results of contrast-enhanced CT (CECT) images.
RESULTS: For both types of T1-weighted sequences and when evaluating the maximum numbers of lesions seen in all imaging sequences, the total numbers of lesions seen were significantly higher in the MnDPDP-enhanced images than in the unenhanced images (p = 0.0005 and p = 0.0001, respectively). The investigators considered the enhanced images to contain "other additional information not found in the unenhanced images" in 279 (45%) of the 621 patients examined. The MnDPDP-enhanced images were also superior to the CECT images in the detection of lesions (p = 0.02). Adverse events were reported by 46 patients (7%) and infusion-associated discomfort by 26 (4%). Heart rates and systolic and diastolic blood pressures showed no clinically significant changes from baseline as a result of the administration of the contrast medium.
CONCLUSION: MnDPDP was shown to be effective and safe in enhanced MR imaging of the liver.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245956     DOI: 10.1080/02841859709172393

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  10 in total

Review 1.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

2.  Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial.

Authors:  Steven S Raman; Christopher Leary; David A Bluemke; Marco Amendola; Dushyant Sahani; Jeffrey D McTavish; Jeffrey Brody; Eric Outwater; Donald Mitchell; Douglas H Sheafor; Jeff Fidler; Isaac R Francis; Richard C Semelka; Kohkan Shamsi; Simone Gschwend; David R Feldman; Josy Breuer
Journal:  J Comput Assist Tomogr       Date:  2010 Mar-Apr       Impact factor: 1.826

Review 3.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

5.  Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging.

Authors:  Young Kon Kim; Seog Wan Ko; Seung Bae Hwang; Chong Soo Kim; Hee Chul Yu
Journal:  Eur Radiol       Date:  2006-02-02       Impact factor: 5.315

6.  Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.

Authors:  Luis Martí-Bonmatí; Amura F Fog; Bart Op de Beeck; Pauline Kane; Hans Fagertun
Journal:  Eur Radiol       Date:  2002-12-19       Impact factor: 5.315

Review 7.  MRI of rod cell compartment-specific function in disease and treatment in vivo.

Authors:  Bruce A Berkowitz; David Bissig; Robin Roberts
Journal:  Prog Retin Eye Res       Date:  2015-09-04       Impact factor: 21.198

8.  Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.

Authors:  Junfeng Wang; Huan Wang; Ian A Ramsay; Derek J Erstad; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  J Med Chem       Date:  2018-09-25       Impact factor: 7.446

9.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

Review 10.  Imaging of liver metastases: MRI.

Authors:  Saravanan Namasivayam; Diego R Martin; Sanjay Saini
Journal:  Cancer Imaging       Date:  2007       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.